RhumbLine Advisers’s Palvella Therapeutics PVLA Stock Holding History

RhumbLine Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.07M	Buy	13,528 +4,399	+48%	+$534K	﹤0.01%	1914
2026 Q1	$1.14M	Buy	9,129 +493	+6%	+$51.4K	﹤0.01%	2126
2025 Q4	$904K	Sell	8,636 -1,235	-13%	-$105K	﹤0.01%	2291
2025 Q3	$619K	Sell	9,871 -85	-0.9%	-$3.79K	﹤0.01%	2550
2025 Q2	$224K	Buy	+9,956	New	+$234K	﹤0.01%	3166
2024 Q1	–	Sell	-23	Closed	-$339	–	4267
2023 Q4	$339	Hold	23	–	–	﹤0.01%	4216
2023 Q3	$556	Hold	23	–	–	﹤0.01%	4225
2023 Q2	$309	Buy	+23	New	+$1.4K	﹤0.01%	4338
2021 Q2	–	Sell	-786	Closed	-$162K	–	3121
2021 Q1	$162K	Buy	786 +1	+0.1%	+$219	﹤0.01%	2874
2020 Q4	$157K	Buy	785 +49	+7%	+$10.2K	﹤0.01%	2898
2020 Q3	$122K	Sell	736 -108	-13%	-$24.6K	﹤0.01%	2834
2020 Q2	$209K	Buy	844 +54	+7%	+$12.6K	﹤0.01%	2748
2020 Q1	$144K	Hold	790	–	–	﹤0.01%	2690
2019 Q4	$229K	Buy	790 +4	+0.5%	+$1.11K	﹤0.01%	2704
2019 Q3	$214K	Sell	786 -6	-0.8%	-$2.32K	﹤0.01%	2729
2019 Q2	$298K	Sell	792 -32	-4%	-$9.55K	﹤0.01%	2609
2019 Q1	$221K	Sell	824 -11	-1%	-$2.61K	﹤0.01%	2708
2018 Q4	$178K	Buy	835 +284	+52%	+$88.1K	﹤0.01%	2765
2018 Q3	$247K	Sell	551 -42	-7%	-$18.3K	﹤0.01%	2619
2018 Q2	$241K	Buy	593 +180	+44%	+$85.7K	﹤0.01%	2647
2018 Q1	$226K	Buy	413 +33	+9%	+$20.4K	﹤0.01%	2556
2017 Q4	$230K	Sell	380 -88	-19%	-$40.9K	﹤0.01%	2576
2017 Q3	$216K	Buy	468 +14	+3%	+$5.98K	﹤0.01%	2693
2017 Q2	$184K	Buy	+454	New	+$133K	﹤0.01%	2787

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

RhumbLine Advisers's PVLA Position: Q2 2026 in Review

RhumbLine Advisers increased its Palvella Therapeutics (PVLA) stake by 48% in Q2 2026, buying an estimated $534K and bringing the position to 13,528 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1914.

RhumbLine Advisers first reported a position in PVLA in Q2 2017 and has held it in 24 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

RhumbLine Advisers held 13,528 shares of Palvella Therapeutics worth $2.07M as of Q2 2026.
RhumbLine Advisers bought 4,399 Palvella Therapeutics shares in Q2 2026, an estimated $534K.
Palvella Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1914 holding.
RhumbLine Advisers first reported a position in Palvella Therapeutics in Q2 2017 and has held it in 24 quarters since.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.